Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Treatment options for patients suffering from indolent forms of mastocytosis remain inadequate with the hyperactivation of mast cells responsible for many of the disease's systemic manifestations. Masitinib is a potent and highly selective oral tyrosine kinase inhibitor. A combined inhibition of c-Kit and Lyn make it particularly efficient in controlling the activity of mast cells and therefore, of potential therapeutic benefit in mastocytosis. Masitinib was administered to 25 patients diagnosed as having systemic or cutaneous mastocytosis with related handicap (i.e., disabilities associated with flushes, depression, pruritus and quality-of-life) at the initial dose levels of 3 or 6 mg/kg/day over 12 weeks. In accordance with the AFIRMM study, response was based upon change of clinical symptoms associated with patient handicap at week 12 relative to baseline, regardless of disease subtype. Improvement was observed in all primary endpoints at week 12 including a reduction of flushes, Hamilton rating, and pruritus as compared with baseline by 64% (P = 0.0005), 43% (P = 0.0049), and 36% (P = 0.0077), respectively. An overall clinical response was observed in 14/25 patients (56%; [95%CI = 37%-75%]), with sustainable improvement observed throughout an extension phase (>60 weeks). Common adverse events were edema (44%), nausea (44%), muscle spasms (28%), and rash (28%), the majority of which were of mild or moderate severity with a significant decline in frequency observed after 12 weeks of treatment. One patient experienced a serious adverse event of reversible agranulocytosis. Masitinib is a promising treatment for indolent forms of mastocytosis with handicap and indicates acceptable tolerability for long-term treatment regimens.
Université Paul Sabatier, Toulouse, France.
Carle
C
Paul
Beatrix
B
Sans
Felipe
F
Suarez
Philippe
P
Casassus
Stéphane
S
Barete
Fanny
F
Lanternier
Catherine
C
Grandpeix-Guyodo
Patrice
P
Dubreuil
Fabienne
F
Palmérini
Colin D
CD
Mansfield
Paul
P
Gineste
Alain
A
Moussy
Olivier
O
Hermine
Olivier
O
Lortholary
D000328:Adult; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D006801:Humans; D008297:Male; D034701:Mastocytosis, Cutaneous / Q000150:complications / Q000188:drug therapy*; D034721:Mastocytosis, Systemic / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D020125:Mutation, Missense; D010880:Piperidines; D011725:Pyridines; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
D001549:Benzamides; D010880:Piperidines; D011725:Pyridines; D013844:Thiazoles; C526575:masitinib